About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:5906908
Allelic
Composition
Stat3tm1Vpo/Stat3tm1Vpo
Tg(Myh6-cre)2182Mds/0
Genetic
Background
involves: 129P2/OlaHsd * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Stat3tm1Vpo mutation (0 available); any Stat3 mutation (72 available)
Tg(Myh6-cre)2182Mds mutation (3 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• about 2/3 of females die after the second pregnancy
• no females survive more than 5 pregnancies
• death always occurs within the first 3 weeks after delivery

cardiovascular system
• myocardial angiogenesis is impaired in postpartum females, with mice showing reduced left ventricle capillary density postpartum compared to controls
• increase in cardiomyocyte length in postpartum females
• extensive cardiac fibrosis in postpartum females
• 4-chamber dilatation in postpartum females
• depressed fractional shorting in postpartum females
• echocardiography indicates left ventricular dilatation and depressed fractional shorting in postpartum females
• all females develop postpartum cardiomyopathy
• treatment with tetrakis (4-benzoic acid) porphyrin (MnTBAP), a pharmacological suppressor of ROS, partially suppresses postpartum cardiomyopathy
• treatment with bromocriptine, a dopamine-D2-receptor agonist and inhibitor of prolactin secretion, prevents postpartum cardiomyopathy and mortality in females
• after 2 pregnancies, the majority of females show signs of overt heart failure such as generalized edema and labored breathing

cellular
• cardiac apoptosis is increased in postpartum females
• hearts of postpartum females exhibit increased oxidative stress

homeostasis/metabolism
• thrombi are often seen in the atria of postpartum females
• females exhibit generalized edema after 2 pregnancies

muscle
• increase in cardiomyocyte length in postpartum females
• depressed fractional shorting in postpartum females
• all females develop postpartum cardiomyopathy
• treatment with tetrakis (4-benzoic acid) porphyrin (MnTBAP), a pharmacological suppressor of ROS, partially suppresses postpartum cardiomyopathy
• treatment with bromocriptine, a dopamine-D2-receptor agonist and inhibitor of prolactin secretion, prevents postpartum cardiomyopathy and mortality in females
• cardiac apoptosis is increased in postpartum females

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
peripartum cardiomyopathy DOID:9997 J:141591


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
11/12/2024
MGI 6.24
The Jackson Laboratory